Actively Recruiting
Diuretic Testing in Chronic Kidney Disease
Led by Erasmus Medical Center · Updated on 2025-08-07
86
Participants Needed
1
Research Sites
239 weeks
Total Duration
On this page
Sponsors
E
Erasmus Medical Center
Lead Sponsor
E
European Research Council
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to predict the progression of chronic kidney disease by diuretic testing in patients with chronic kidney disease. The main questions it aims to answer are: Does a worse result of a diuretic test predict the progression of chronic kidney disease? If there is a comparison group: Researchers will compare the diuretic test in patients with chronic kidney disease to healthy participants to see if the results are different in a healthy kidney. Participants will undergo diuretic testing. This involves the administration of bumetanide and hydrochlorothiazide with subsequent blood and urine collections.
CONDITIONS
Official Title
Diuretic Testing in Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults with chronic kidney disease stage G3 (creatinine-based eGFR 30-59 mL/min/1.73m2) at their last outpatient visit
- Healthy adults with eGFR within the expected range for their age (normal age-related decline of 1 ml/min/1.73 m2 per year starting from age 40)
You will not qualify if you...
- Known allergy or intolerance to bumetanide or hydrochlorothiazide
- Currently undergoing systemic chemotherapy for cancer
- Kidney transplant recipient
- Use of calcineurin-inhibitors
- Life expectancy less than 12 months
- Receiving immunosuppressive treatment for glomerulonephritis
- Unable to follow study instructions or deemed incapacitated
- Low or high potassium levels (K+ less than 3.0 mmol/L or greater than 5.5 mmol/L) at inclusion
- Low or high sodium levels (Na+ less than 130 mmol/L or greater than 150 mmol/L) at inclusion
- Tubulopathy inherited as cause of chronic kidney disease
- Polycystic kidney disease or tubulointerstitial kidney disease causing chronic kidney disease
- Clinically relevant heart failure (New York Heart Association class III or IV)
- Therapy-resistant hypertension with systolic blood pressure over 180 mmHg at inclusion
- Current treatment with inhibitors of organic anion transporters such as probenecid, pravastatin, cimetidine, cephalosporins, or acetazolamide
- Active hepatitis during last outpatient visit
- Advanced liver cirrhosis (Child-Pugh B or C)
- Active drug or alcohol abuse
- Unable to tolerate a 28-day washout of drugs that interfere with diuretic testing
- Women who are pregnant, breastfeeding, or planning pregnancy before the test day
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Erasmus MC
Rotterdam, South Holland, Netherlands, 3015GD
Actively Recruiting
Research Team
S
Sebastian B Beckmann, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here